Innate Pharma Files 6-K, Issues Press Release
Ticker: IPHYF · Form: 6-K · Filed: Nov 20, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a press release today, check the 6-K for details.
AI Summary
Innate Pharma S.A. filed a Form 6-K on November 20, 2024, to report a press release dated the same day. The filing does not contain specific financial figures or operational updates within the provided text, but it serves as a notification of the press release's issuance.
Why It Matters
This filing indicates Innate Pharma is making a public announcement, which could contain material information for investors regarding its business or pipeline.
Risk Assessment
Risk Level: low — The filing is a routine submission of a press release and does not contain inherently risky information itself.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- November 20, 2024 (date) — Date of report
- 001-39084 (other) — Commission File Number
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by Innate Pharma S.A. on November 20, 2024.
What is the Commission File Number for Innate Pharma S.A.?
The Commission File Number for Innate Pharma S.A. is 001-39084.
Does this filing include an annual report?
No, this filing is a Form 6-K, which is a report of a foreign private issuer. Innate Pharma S.A. indicates it files annual reports under cover of Form 20-F.
What is the address of Innate Pharma S.A.'s principal executive office?
The address of Innate Pharma S.A.'s principal executive office is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated November 20, 2024, is included with this 6-K filing.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-11-20 06:02:19
Filing Documents
- a6k-iphx241120.htm (6-K) — 8KB
- exhibit991-241120.htm (EX-99.1) — 16KB
- 0001598599-24-000092.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date November 20, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer